Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Viking Therapeutics is favored over Axsome Therapeutics for long-term investors due to VK2735's Phase 3 obesity program and substantially larger potential addressable market, despite its pre-revenue clinical-stage risk. Axsome generated FY2025 revenue of $638.5 million, up 65.5% year over year, but posted a $183.2 million net loss, negative $93.9 million free cash flow, and debt-to-equity of 2.7x. Viking reported no revenue and a $359.6 million net loss, but holds no debt and a 9.3x current ratio, providing a stronger liquidity runway while it funds obesity-drug development.

Analysis

AXSM’s investment case is now primarily an operating-leverage debate, not a pipeline story: commercial spending must begin growing materially slower than prescriptions for the equity to rerate from a cash-burning specialty-pharma multiple toward profitable CNS peers. Its leverage makes this asymmetrical in both directions—an incremental revenue miss can force a longer period of cash burn and constrain business-development flexibility, while demonstrated EBITDA inflection could drive a sharp multiple expansion. The more relevant competitive risk is payer step-editing and formulary pressure from branded and generic CNS alternatives, rather than direct competition with large-cap pharma alone.

VKTX offers obesity optionality, but the market should value it as a probability-weighted asset rather than a smaller version of LLY or NVO. Success in late-stage development would still leave manufacturing capacity, reimbursement access, and differentiation versus rapidly improving incretin regimens as the principal determinants of peak sales; efficacy alone is insufficient. LGND is a modest second-order beneficiary because a higher probability of VKTX commercialization increases royalty/contract-value visibility without requiring LGND to fund obesity trials.

The contrarian setup favors AXSM if investors are extrapolating near-term selling expense without recognizing that a fixed commercial infrastructure can support additional indications and products. Conversely, VKTX may be vulnerable to de-risking only if trial data exceed expectations: obesity-development valuations increasingly embed scarcity value, while LLY/NVO’s scale can compress the economic value of a clinically competitive but commercially undifferentiated entrant. Over the next 1-3 months, earnings guidance and trial-enrollment updates matter most; over 6-18 months, AXSM’s cash-flow conversion and VKTX’s pivotal efficacy, tolerability, and discontinuation profile determine outcomes.

Key Decisions for Investors

• Maintain a modest long AXSM bias into the next two earnings reports only if prescription growth remains ahead of commercial-expense growth; target a 6-12 month rerating on evidence of narrowing cash burn. Exit if management raises operating-expense guidance without a commensurate revenue-guide increase, or if liquidity covenants become a discussion point.
• Treat VKTX as a catalyst position, not a core obesity allocation: use defined-risk call spreads expiring 1-3 months after the next material pivotal-data or regulatory milestone, sized for a full premium loss. Do not chase common shares absent updated valuation, cash-runway, and trial-timeline data.
• For diversified obesity exposure, prefer LLY or NVO as the core holding and fund a small VKTX option position from that allocation; this preserves category upside while limiting single-asset clinical, manufacturing, and commercialization risk.
• Add LGND to the watchlist rather than initiating solely on VKTX optimism. Reassess after disclosure of any milestone, royalty-rate, or sublicense economics that can translate VKTX probability changes into quantifiable earnings sensitivity.
• Consider a conditional 6-12 month relative-value trade long AXSM / short VKTX only if VKTX materially outperforms ahead of data while AXSM demonstrates sequential improvement in operating leverage; the thesis is falsified by superior VKTX pivotal differentiation or renewed AXSM revenue/guidance misses.